Transplantation of Autologous Oral Mucosal Epithelial Stem Cell Sheet for Treating Limbal Stem Cell Deficiency Disease
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Limbal Stem Cell Deficiency
- Sponsor
- He Eye Hospital
- Enrollment
- 7
- Primary Endpoint
- The area of reepithelialization of corneal epithelium
- Last Updated
- 9 years ago
Overview
Brief Summary
The aim of this trials investigates the therapeutic effects of application autologous oral mucosal epithelial cell sheets in the treatment of limbal stem cell deficiency disease.
Detailed Description
A number of external factors can result in limbal stem cell deficiency(LSCD), causing pain, pathological corneal epithelium regeneration, inflammation reaction and seriously visual loss. For patients with unilaterally damaged eye, transplantation of limbal tissue from the healthy eye can be used in the past years in the risk of inducing limbal stem cell damaged in the healthy eye. While graft of human leukocyte antigen matched allogenic limbal stem cells require immune suppressive medications, it can cause side effects in the body. Over the past 10 years, the clinical trials of application of cultured autologous oral mucosal epithelial cell sheet to treat LSCD have been emerged as a promising strategy in many countries. However, little study has been reported in China. This study investigates the therapeutic effects of application autologous oral mucosal epithelial cell sheets in the treatment of limbal stem cell deficiency disease in China.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Male or female aged\>=18 years old
- •Normal intraocular pressure
- •Normal Eyelid
- •No cataract and retinal disease
- •No ulcers and tumor in the mouth
Exclusion Criteria
- •Severe Systemic infection
- •History of acute phase of ocular and oral inflammation
- •History of hyper sensibility or allergy to antibiotics or serum
- •Women who are or may be pregnant
- •Patients with infectious diseases
- •Patients with other complications
Outcomes
Primary Outcomes
The area of reepithelialization of corneal epithelium
Time Frame: 3 months
The preoperative status of the eye will be recorded on the basis of clinical drawings and pre-and post-operative photographs. These pictures will be sent to two corneal experts in order to evaluate the results. Judgement criterion: the results will be tested with a slit lamp: Normal: no epithelial loss; Mild: the area of epithelial loss \<1/3; Moderate: the area of epithelial loss \>1/3 \<2/3; Severe: the area of epithelial loss\> 2/3
Secondary Outcomes
- Improvement of best correct visual acuity(one year)
- Decrease of corneal neovascularization(one year)